# Spero Therapeutics (SPRO) — Earnings

SPRO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/spro/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.16 |
| EPS estimate | −$0.17 |
| EPS surprise | +5.88% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Aug 12, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1701108/000119312526346795/spro-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/9e092fc1-f415-8e21-2268-ca0f44e4ef80.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 12, 2026 | −$0.17 | −$0.16 | 5.88% | — | — |
| Q1 2026 | May 13, 2026 | −$0.18 | −$0.13 | 27.78% | — | $258,000.00 |
| Q4 2025 | Mar 26, 2026 | −$0.20 | $0.53 | 365.00% | $26.0M | $41.3M |
| Q3 2025 | Nov 13, 2025 | −$0.25 | −$0.13 | 48.00% | $12.0M | $5.4M |
| Q2 2025 | Aug 12, 2025 | −$0.38 | −$0.03 | 92.11% | $11.0M | $14.2M |
| Q1 2025 | May 13, 2025 | −$0.55 | −$0.25 | 54.55% | $11.0M | $5.9M |
| Q4 2024 | Mar 27, 2025 | −$0.31 | −$0.38 | -22.58% | $12.4M | $15.0M |
| Q3 2024 | Nov 14, 2024 | −$0.27 | −$0.32 | -20.75% | $23.0M | $13.5M |
| Q2 2024 | Aug 5, 2024 | −$0.38 | −$0.33 | 13.16% | $4.9M | $10.2M |
| Q1 2024 | May 15, 2024 | −$0.04 | −$0.24 | -454.27% | $21.5M | $9.3M |
| Q4 2023 | Mar 13, 2024 | −$0.10 | $0.96 | 1060.00% | $18.6M | $73.5M |
| Q3 2023 | Nov 13, 2023 | −$0.03 | −$0.06 | -100.00% | $15.0M | $25.5M |
| Q2 2023 | Aug 10, 2023 | −$0.34 | −$0.23 | 33.00% | $1.1M | $2.7M |
| Q1 2023 | May 11, 2023 | −$0.33 | −$0.25 | 24.99% | $1.3M | $2.1M |
| Q4 2022 | Mar 30, 2023 | −$0.35 | $0.55 | 255.68% | $866,667.00 | $47.4M |
| Q3 2022 | Nov 14, 2022 | −$0.30 | −$0.33 | -8.80% | $5.4M | $2.0M |
| Q2 2022 | Aug 10, 2022 | −$0.93 | −$0.87 | 6.12% | $1.4M | $2.0M |
| Q1 2022 | May 16, 2022 | −$0.93 | −$1.01 | -8.60% | $1.9M | $2.1M |
| Q4 2021 | Mar 31, 2022 | −$0.75 | −$0.90 | -20.40% | $5.0M | $2.7M |
| Q3 2021 | Nov 10, 2021 | −$0.66 | −$0.70 | -5.53% | $4.5M | $3.1M |

## Frequently Asked Questions

### When did Spero Therapeutics (SPRO) last report earnings?

Spero Therapeutics last reported on Aug 12, 2026, covering fiscal Q2 2026.

### Did SPRO beat earnings estimates?

Yes. Spero Therapeutics reported EPS of −$0.16 for Q2 2026 against a −$0.17 estimate — a 5.88% beat.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).